Funding
Amounts as reported; USD estimates shown only when they matchListed 1 funding record. Latest funding: $188M (Series E), Aug 6, 2026.
Annual trendUnit: USD
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 6, 2026 | $188M · Series E | 1 source Source ↗ | |
Evidence LifeMine Therapeutics Raises $188M Series EOn August 6, 2026, per Labiotech, natural product drug discovery company LifeMine Therapeutics raised $188M in a Series E. Industry coverage in September 2026 noted an additional ~$75M Series D during August; the two rounds should not be combined into a single figure. Details are subject to company announcements. Translated source brief, not a quotation. Check the original before citing. Sources · 1
| |||
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 1 valuation record.
Annual trendUnit: USD
No chartable valuation estimates yet.
1 listed record lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 6, 2026 | — · Series E | 1 source Source ↗ | |
Evidence LifeMine Therapeutics Raises $188M Series EOn August 6, 2026, per Labiotech, natural product drug discovery company LifeMine Therapeutics raised $188M in a Series E. Industry coverage in September 2026 noted an additional ~$75M Series D during August; the two rounds should not be combined into a single figure. Details are subject to company announcements. Translated source brief, not a quotation. Check the original before citing. Sources · 1
| |||
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchNo revenue records are listed yet.
No revenue rows to list.
Team, products & investors
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.